Genmab — Februar 2021

[JørgenVarnæs]

In other words - we are “buying” a factory

[E_L]

can we call it research lab please...

[JørgenVarnæs]

Well, there is finally need for substantial production of molecules to feed the clinical programs

[JørgenVarnæs]

That can’t be handled in research labs

[E_L]

will they not outsource that?

[JørgenVarnæs]

That’s why i wrote “buying”

[E_L]

lol, don't lie, you were trying to make us nervous by using the word factory

[JørgenVarnæs]

Absolutely - with the difference that buying a factory is not COMPLETELY insane now. Just insane

[E_L]

they should have never sold it, worth a fortune now

[Klarussen]

Selv om kursen falder, så husk at for hver aktie der sælges, købes den igen af en håbefuld investor der tror på casen. Bliver teknisk interessant at se hvor bunden denne gang ligger. Lige nu synes det noget uklart.

[Bulder]

Jo mere man kigger på prognosen, jo mere ser man, at den ikke kunne være meget anderledes. Man kan jo ikke lade programmerne tørre ud. Man er nødt til at følge dem til dørs. Og det koster penge. Eneste anke er en lidt svag dara salgsprognose.

[E_L]

what was your guess for Dara sales?

[Solsen]

Den har jeg tænkt mig at spørge til

[Bulder]

Was hoping for 5,5-5,8

[Solsen]

4 x Q420 er urimelig tæt på den nedre guidance. Vi har en ny indikation i 2021 og det burde give lidt mere i min bog.

[Bulder]

Ja, og jeg ville hellere have en højere prognose nu i stedet for opjusteringer senere.

[Solsen]

Der er ikke relief i aktien....

[E_L]

ok, i agree. but your mid-point is less then 5% off, at the start of a year that is in the midst of a pandemic, it isn't that much

[E_L]

if they get to their top of the range, like they did last year, they are practically at your mid point

[GeorgeBest]

UBS beholder køb og målkurs på 2630